Search Results - "Festen, E"

The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1 by Imhann, Floris, Van der Velde, K J, Barbieri, R, Alberts, R, Voskuil, M D, Vich Vila, A, Collij, V, Spekhorst, L M, Van der Sloot, K W J, Peters, V, Van Dullemen, H M, Visschedijk, M C, Festen, E A M, Swertz, M A, Dijkstra, G, Weersma, R K

“…Inflammatory bowel disease (IBD) is a chronic complex disease of the gastrointestinal tract. Patients with IBD can experience a wide range of symptoms, but the…”
Get full text

Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar by Buurman, D J, Blokzijl, T, Festen, E A M, Pham, B T, Faber, K N, Brouwer, E, Dijkstra, G

“…TNF-α-neutralizing antibodies, such as infliximab (IFX) and adalimumab (ADA), are effective in the treatment of inflammatory bowel diseases (IBD), but they are…”
Get full text

Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis by Festen, E A M, Goyette, P, Scott, R, Annese, V, Zhernakova, A, Lian, J, Lefèbvre, C, Brant, S R, Cho, J H, Silverberg, M S, Taylor, K D, de Jong, D J, Stokkers, P C, Mcgovern, D, Palmieri, O, Achkar, J-P, Xavier, R J, Daly, M J, Duerr, R H, Wijmenga, C, Weersma, R K, Rioux, J D

“…Genetic susceptibility is known to play a large part in the predisposition to the inflammatory bowel diseases (IBDs) known as Crohn's disease (CD) and…”
Get more information

Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort by Weersma, R K, Stokkers, P C F, van Bodegraven, A A, van Hogezand, R A, Verspaget, H W, de Jong, D J, van der Woude, C J, Oldenburg, B, Linskens, R K, Festen, E A M, van der Steege, G, Hommes, D W, Crusius, J B A, Wijmenga, C, Nolte, I M, Dijkstra, G

“…Crohn's disease and ulcerative colitis have a complex genetic background. We assessed the risk for both the development and severity of the disease by…”
Get more information

Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes by Voskuil, M D, Spekhorst, L M, van der Sloot, K W J, Jansen, B H, Dijkstra, G, van der Woude, C J, Hoentjen, F, Pierik, M J, van der Meulen, A E, de Boer, N K H, Löwenberg, M, Oldenburg, B, Festen, E A M, Weersma, R K

“…Abstract Background and Aims Inflammatory bowel disease [IBD] phenotypes are very heterogeneous between patients, and current clinical and molecular…”
Get full text

A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease by Gacesa, R., Vich Vila, A., Collij, V., Mujagic, Z., Kurilshikov, A., Voskuil, M.D., Festen, E.A.M., Wijmenga, C., Jonkers, D.M.A.E., Dijkstra, G., Fu, J., Zhernakova, A., Imhann, F., Weersma, R.K.

“…Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) show a large overlap in clinical presentation, which presents diagnostic challenges. As a…”
Get full text

How will insights from genetics translate to clinical practice in inflammatory bowel disease? by Festen, E.A.M., MD, PhD, Weersma, R.K., MD, PhD

“…Abstract Inflammatory bowel disease, consisting of Crohn's disease and ulcerative colitis, is a chronic inflammatory disease of the gut, which arises through…”
Get full text

Correction to: The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1 by Imhann, Floris, Van der Velde, K J, Barbieri, R, Alberts, R, Voskuil, M D, Vila, A Vich, Collij, V, Spekhorst, L M, Van der Sloot, K W J, Peters, V, Van Dullemen, H M, Visschedijk, M C, Festen, E A M, Swertz, M A, Dijkstra, G, Weersma, R K

“…Following publication of the original article [1], the authors…”
Get full text

Association of Crohn's disease-associated NOD2 variants with intestinal failure requiring small bowel transplantation and clinical outcomes by Janse, M, Weersma, R K, Sudan, D L, Festen, E A M, Wijmenga, C, Dijkstra, G, Mercer, D

Get more information

The Impact of Ethnicity and Country of Birth on Inflammatory Bowel Disease Phenotype: a Prospective Cohort Study by Spekhorst, L M, Severs, M, de Boer, N K H, Festen, E A M, Fidder, H H, Hoentjen, F, Imhann, F, de Jong, D J, van der Meulen-de Jong, A E, Pierik, M J, van der Woude, C J, Dijkstra, G, Ponsioen, C Y, Löwenberg, M, Oldenburg, B, Weersma, R K

“…The number of patients with inflammatory bowel disease [IBD], of non-Caucasian descent in Western Europe, is increasing. We aimed to explore the impact of…”
Get full text

Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size by Esposito‐Festen, J. E., Zanen, P., Tiddens, H. A. W. M., Lammers, J.‐W. J.

“…What is already known about this subject • For asthmatic adults, bronchodilators with a MMAD between 3 and 6 µm were shown to give the best improvement in lung…”
Get full text

Association of DLG5 variants with gluten-sensitive enteropathy by Festen, E A, Zhernakova, A, Wijmenga, C, Weersma, R K

Get more information

P1159 Gene and environment interactions in inflammatory bowel disease: a systematic review of human epidemiologic studies by Bai, J, Bouwknegt, D, Weersma, R, Dijkstra, G, van der Sloot, K, Festen, E

“…Abstract Background Complex gene-environment interaction for Inflammatory Bowel Disease (IBD) remains elusive. This systematic review aims to summarize the…”
Get full text

Cognitive functioning in bilateral perisylvian polymicrogyria (BPP): clinical and radiological correlations by Jansen, An C., Leonard, Gabriel, Bastos, Alexandre C., Esposito-Festen, Josée E., Tampieri, Donatella, Watkins, Kate, Andermann, Frederick, Andermann, Eva

“…Bilateral perisylvian polymicrogyria (BPP) is a malformation of cortical development, frequently associated with severe dysarthria or anarthria. BPP patients…”
Get full text

Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-[alpha] biologicals and an Infliximab-biosimilar by Buurman, D. J, Blokzijl, T, Festen, E. A. M, Pham, B. T, Faber, K. N, Brouwer, E, Dijkstra, G

“…Introduction TNF-[alpha]-neutralizing antibodies, such as infliximab (IFX) and adalimumab (ADA), are effective in the treatment of inflammatory bowel diseases…”
Get full text

P812 Fluorescently labelled vedolizumab identified macroscopic and microscopic mucosal drug distribution in patients with inflammatory bowel disease by Van Der Waaij, A, Gabriëls, R, Linssen, M, Volkmer, P, Robinson, D, Hermoso, M, Karrenbeld, A, Festen, E, Dijkstra, G, Kats-Urgulu, G, Nagengast, W

“…Abstract Background Biological treatment in inflammatory bowel disease (IBD) patients is currently hampered by high non-response rates. To enhance personalized…”
Get full text

DOP69 Longitudinal gut microbiome dynamics in relation to disease flares in Inflammatory Bowel Disease, pilot data from the IBD-Tracker study by Gacesa, R, Klaassen, M A Y, Collij, V, Björk, J R, Blankenstein, A D, Jansen, B H, Dijkstra, G, Visschedijk, M, Festen, E A M, Ananthakrishnan, A, Alm, E, Weersma, R K

“…Abstract Background The pathogenetic mechanisms that lead to IBD flares are unknown and the absence of reliable predictive biomarkers results in a therapeutic…”
Get full text

P301 Distinct plasma proteomic biomarkers associate with disease progression in patients with Inflammatory Bowel Diseases by Veenstra, F E, Hu, S, van Dullemen, H M, Visschedijk, M C, Faber, K N, Dijkstra, G, Samsom, J N, Festen, E A M, Weersma, R K, Spekhorst, L M, Bourgonje, A R

“…Abstract Background Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are characterized by complex…”
Get full text

P193 Fatigued patients with Inflammatory Bowel Disease exhibit distinct systemic antibody epitope repertoires by Griesbaum, M G, Vogl, T, Andreu-Sánchez, S, Klompus, S, Kalka, I N, Leviatan, S, van Dullemen, H M, Visschedijk, M C, Festen, E A M, Faber, K N, Dijkstra, G, Weinberger, A, Segal, E, Weersma, R K, Bourgonje, A R

“…Abstract Background Patients with inflammatory bowel diseases (IBD) frequently experience fatigue, affecting up to 80% of those with active disease and…”
Get full text

P033 Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment by Karmi, N, Sun, S, de Jong, S, Bangma, A, Teunis, J, Paraskevopoulou, M, Juarez, J, Bleck, B, Farahmand, S, Weersma, R, Bigaeva, E, Festen, E

“…Abstract Background Vedolizumab (VDZ), a monoclonal antibody that targets α4β7 integrin, was approved to treat moderate-to-severe ulcerative colitis (UC) based…”
Get full text